Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.

Beth E MeyersonKeith G BenteleDanielle M RussellBenjamin R BradyMissy DownerRoberto C GarciaIrene GarnettRebecca LutzArlene MahoneySavannah SamoranoChristina ArredondoHoney J AndresHaley ColesBrenda Granillo

Published in: PloS one (2022)

MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. To understand the impact of these recommended treatment changes in Arizona, and other states where they were not well implemented, federal and state regulators must mandate these changes and support MOUD providers to implement them.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
combination therapy
patient reported
replacement therapy